Study Examines Donepezil’s Risk of Rhabdomyolysis and Hospital Admissions

Dementia: An Overview

A recent study explored the link between donepezil, a widely used medication for dementia, and the risk of hospital admissions due to potential side effects. Dementia significantly affects the aging population globally, with nearly 10 million new cases diagnosed each year. This condition encompasses various symptoms that impair cognitive functions such as memory, communication, and daily activities. Alzheimer’s disease, a progressive brain disorder, represents the majority of dementia cases.

Donepezil: A Common Treatment

Donepezil, classified as a cholinesterase inhibitor, is among the most frequently prescribed drugs for alleviating symptoms of Alzheimer’s disease and other forms of dementia. However, health authorities, including Health Canada and international regulatory agencies, have raised concerns regarding the risk of rhabdomyolysis as a side effect of donepezil. These concerns stem from case reports indicating that most instances of rhabdomyolysis occurred either after the initial dose or following an increase in dosage.

Understanding Rhabdomyolysis

Rhabdomyolysis involves the breakdown of damaged skeletal muscle, which can lead to kidney complications. Early detection is crucial for successful treatment, typically involving intravenous (IV) therapy to administer fluids. In severe cases, patients may require acute dialysis for kidney damage management.

Research Methodology

In a study published in the Canadian Medical Association Journal, researchers sought to ascertain whether the risk of rhabdomyolysis-related hospital admissions was higher with donepezil compared to other cholinesterase inhibitors like rivastigmine or galantamine. The study focused on a cohort of patients aged 66 or older in Ontario, Canada, who were prescribed donepezil, rivastigmine, or galantamine for the first time. Data was collected from various healthcare databases, encompassing over 220,000 individuals from 2002 to 2017. Patients were categorized into two groups based on their prescriptions: one for donepezil and the other for rivastigmine or galantamine.

Study Findings

The findings revealed that the risk of hospitalization due to rhabdomyolysis was doubled for patients taking donepezil compared to those on rivastigmine or galantamine. Notably, most hospital admissions within 30 days of starting donepezil did not involve severe cases of rhabdomyolysis, and no patients required treatment for kidney damage. Although the overall risk of hospitalization linked to donepezil was small, it remained statistically significant when compared to the other medications.

Conclusion of the Study

With a robust sample size of over 150,000 patients using donepezil, the researchers were able to investigate a potential side effect that could pose serious health risks. The authors concluded, “The findings of this population-based cohort study support regulatory agency warnings about the risk of donepezil-induced rhabdomyolysis.” Furthermore, they noted that the likelihood of developing severe side effects within 30 days of starting donepezil was low.

References

Fleet, J.L., McArthur, E., Patel, A., Weir, M.A., Montero-Odasso, M., and Garg, A.X. (2019). Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. CMAJ. doi: 10.1503/cmaj.190337
Commonly used drug for Alzheimer’s disease doubles risk of hospitalization. (2019, September 16). Retrieved from https://www.eurekalert.org/pub_releases/2019-09/ji-cud091019.php
Dementia and Alzheimer’s: What Are the Differences. https://www.healthline.com/health/alzheimers-disease/difference-dementia-alzheimers#dementia
Rhabdomyolysis: Causes, Symptoms, and Diagnosis. https://www.healthline.com/health/rhabdomyolysis
Image by Parentingupstream from Pixabay